CRISPR Therapeutics (CRSP) Earnings Date, Estimates & Call Transcripts $65.13 +10.04 (+18.22%) Closing price 04:00 PM EasternExtended Trading$64.90 -0.23 (-0.35%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CRISPR Therapeutics Earnings Summary CRISPR Therapeutics issued Q1 2025 earnings on May 6, 2025, reporting an EPS of -$1.58, which missed the consensus estimate of -$1.27 by $0.31. Its revenue for the quarter was up 71.6% on a year-over-year basis. With a trailing EPS of -$4.52, CRISPR Therapeutics' earnings are expected to grow next year, from ($5.16) to ($4.03) per share. Upcoming Q2 Earnings DateAug. 4Before Market OpensEstimatedConsensus EPS (May. 6) -$1.27 Actual EPS (May. 6) -$1.58 Missed By -$0.31 Q1 2025 Earnings ResourcesQ1 2025 Earnings Report Press Release (8-K) Quarterly Report (10-Q)CRSP Upcoming EarningsCRISPR Therapeutics' Q2 2025 earnings is scheduled for Monday, August 4, 2025, with a conference call scheduled on Tuesday, August 5, 2025 at 12:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Powered by Get CRISPR Therapeutics Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on CRISPR Therapeutics and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataCRSP Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.CRSP Estimated and Actual Revenue by QuarterEstimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. CRISPR Therapeutics Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20255-$1.60-$0.74-$1.17Q2 20255-$1.74-$0.93-$1.39Q3 20255-$1.55-$1.07-$1.28Q4 20255-$1.35-$1.03-$1.21 FY 2025 20 -$6.24 -$3.77 -$5.05 Q1 20263-$1.56-$0.93-$1.18Q2 20263-$1.59-$0.89-$1.15Q3 20263-$1.33-$0.76-$1.04Q4 20263-$1.18-$0.67-$0.93 FY 2026 12 -$5.66 -$3.25 -$4.31 Q1 20271-$1.47-$1.47-$1.47 CRISPR Therapeutics Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame Start Date End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails 8/4/2025(Estimated)--------5/6/2025Q1 2025-$1.27-$1.58 -$0.31-$1.58--2/11/2025Q4 2024-$1.15-$0.44+$0.71-$0.44--11/5/2024Q3 2024-$1.42-$1.01+$0.41-$1.01$6.65M$0.60M8/5/2024Q2 2024-$1.43-$1.49 -$0.06-$1.49$12.31M$0.52M5/8/2024Q1 2024-$1.35-$1.43 -$0.08-$1.43$25.53M$0.50M2/21/2024Q4 2023$0.15$1.10+$0.95$1.10$148.72M$201.20M11/6/2023Q3 2023-$2.04-$1.41+$0.63-$1.41$5.05M-8/7/2023Q2 2023-$2.13-$0.98+$1.15-$0.98$1.80M$70.00M CRISPR Therapeutics Earnings - Frequently Asked Questions When is CRISPR Therapeutics' earnings date? CRISPR Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Monday, August 4th, 2025 based off last year's report dates. Learn more on CRSP's earnings history. Did CRISPR Therapeutics beat their earnings estimates last quarter? In the previous quarter, CRISPR Therapeutics (NASDAQ:CRSP) missed the analysts' consensus estimate of ($1.27) by $0.31 with a reported earnings per share (EPS) of ($1.58). Learn more on analysts' earnings estimate vs. CRSP's actual earnings. How much revenue does CRISPR Therapeutics generate each year? CRISPR Therapeutics (NASDAQ:CRSP) has a recorded annual revenue of $37.31 million. How much profit does CRISPR Therapeutics generate each year? CRISPR Therapeutics (NASDAQ:CRSP) has a recorded net income of -$366.25 million. CRSP has generated -$4.52 earnings per share over the last four quarters. What is CRISPR Therapeutics' EPS forecast for next year? CRISPR Therapeutics' earnings are expected to grow from ($5.16) per share to ($4.03) per share in the next year. More Earnings Resources from MarketBeat Related Companies Allogene Therapeutics Earnings Date Axsome Therapeutics Earnings Date Beam Therapeutics Earnings Date Editas Medicine Earnings Date KALA BIO Earnings Date Moderna Earnings Date Intellia Therapeutics Earnings Date Vertex Pharmaceuticals Earnings Date Insmed Earnings Date Teva Pharmaceutical Industries Earnings Date Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Netflix Q2 2025 Earnings: What Investors Need to KnowHow Goldman Sachs Earnings Help You Strategize Your PortfolioCitigroup Earnings Could Signal What’s Next for Markets3 Analysts Set $600 Target Ahead of Microsoft EarningsTesla: 2 Plays Ahead of Next Week's Earnings ReportFastenal Surges After Earnings Beat, Tariff Risks Loom3 Catalysts Converge on Intel Ahead of a Critical Earnings Report This page (NASDAQ:CRSP) was last updated on 7/18/2025 by MarketBeat.com Staff From Our Partners[ATTENTION] This Crypto Rocket Is About Launch…Every crypto bull market ends with a final surge — the window where fortunes are made fast. According to tw...Crypto Swap Profits | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredHedge fund legend humiliates Bitcoin tradersLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredFREE BUY ALERT: These 3 tiny AI stocks could surgeWe're living in unprecedented times. Most people think it's too late to get into AI right now … That the...Weiss Ratings | SponsoredWill I be blacklisted?Porter Stansberry says a financial force bigger than 9/11 or COVID is already ripping through America — and mo...Porter & Company | SponsoredWhen your faith is put to the test, what will you do?Former CIA advisor Jim Rickards believes President Trump has just unlocked what the Bible foretold — a $150 tr...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CRISPR Therapeutics AG Please log in to your account or sign up in order to add this asset to your watchlist. Share CRISPR Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
